Akawi N, McRae J, Ansari M, Balasubramanian M, Blyth M, Brady AF, et al. Discovery of four recessive developmental disorders by probabilistic matching of genotypes and phenotypes among 4125 families. Nat Genet. 2015;47:1363–9.
Academic google
Kernohan KD, McBride A, Xi Y, Martin N, Schwartzentruber J, Dyment DA, et al. Loss of arginine methyltranserase PRMT7 causes syndromic intellectual disability with microcephaly and brachydactyly. Clin Genet. 2017;91:708–16.
Academic google
Agolini E, Dentici ML, Bellacchio E, Alesi V, Radio FC, Torella A, et al. Broadening the clinical and molecular spectrum of PRMT7 mutations: three additional patients and review. Clin Genet. 2018;93:675–81.
Academic google
Valenzuela I, Segura-Puimedon M, Rodríguez-Santiago B, Fernández-Alvarez P, Vendrell T, Armengol L, et al. Further delineation of the phenotype caused by loss-of-function mutations in PRMT7. Eur J Med Genet. 2019;62:182–5.
Academic google
Birnbaum R, Yosha-Orpaz N, Yanoov-Sharav M, Kidron D, Gur H, Yosovich K, et al. Prenatal and postnatal presentation of PRMT7-related syndrome: expansion of phenotypic manifestations. Am J Med Genet A 2019;179:78–84.
Academic google
Poquérusse J, Whitford W, Taylor J, Alburaiky S, Snell RG, Lehnert K, et al. New PRMT7 mutation in a rare case of dysmorphism and intellectual disability. J Hum Genet. 2022;67:19–26.
Academic google
Bertino E, Spada E, Occhi L, Coscia A, Giuliani F, Gagliardi L, et al. Neonatal Anthropometric Charts: The Italian neonatal study compared with other European studies. J Pediatr Gastroenterol Nutr. 2010;51:353–61.
Academic google
Growth calculator 4. [Online] http://www.weboriented.it/gh4/.
Tanner JM. Assessment of Skeletal Maturity and Prediction of Adult Height (TW2 Method). 2. Academic Press; 1983.
Academic google
Linglart A, Levine MA, Jüppner H. Pseudohypoparathyroidism. Endocrinol Metab Clin North Am. 2018;47:865–88.
Academic google
Mantovani G, de Sanctis L, Barbieri AM, Elli FM, Bollati V, Vaira V, et al. Pseudohypoparathyroidism and GNAS epigenetic defects: clinical evaluation of Albright’s hereditary osteodystrophy and molecular analysis in 40 patients. J Clin Endocrinol Metab. 2010;95:651–8.
Academic google
Linglart A, Maupetit-Méhouas S, Silve C. GNAS: disorders related to loss of function and the role of imprinting. Horm Res Pediatrics. 2013;79:119–29.
Academic google
Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the infant born small for gestational age to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Research Society of Pediatric Endocrinology. Growth hormone. J Clin Endocrinol Metab. 2007;92:804–10.
Academic google
De Ridder MA, Stijnen T, Hokken-Koelega AC. Prediction of adult height in growth hormone-treated children with growth hormone deficiency. J Clin Endocrinol Metab. 2007;92:925–31.
Academic google
Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A. Adult height after prolonged and continuous growth hormone (GH) treatment in infants born small for gestational age: results of a study. Randomized double-blind dose-response trial of GH. J Clin Endocrinol Metab. 2003;88:3584–90.
Academic google
Ranke MB, Lindberg A. KIGS International Board. Observed and predicted growth responses in prepubertal children with growth disorders: guiding growth hormone treatment by empirical variables. J Clin Endocrinol Metab. 2010;95:1229–37.
Academic google
Bang P, Ahmed SF, Argente J, Backeljauw P, Bettendorf M, Bona G, et al. Identification and management of poor response to growth promotion therapy in children with short stature. Clin Endocrinol (Oxf). 2012;77:169–81.
Kelnar CJ. Growth hormone therapy in Noonan syndrome. Horm Res. 2000;53:77–81.
Academic google
Muthuvel G, Dauber A, Alexandrou E, Tyzinski L, Andrew M, Hwa V, et al. Treatment of short stature in aggrecan-deficient patients with recombinant human growth hormone: one-year response. J Clin Endocrinol Metab. 2022;107:e2103–9.
Academic google
Savage MO, Burren CP, Rosenfeld RG. The continuum of growth hormone-IGF-I axis defects causing short stature: diagnostic and therapeutic challenges. Clin Endocrinol (Oxf). 2010;72:721–8.
Ozono K, Ogata T, Horikawa R, Matsubara Y, Ogawa Y, Nishijima K. Efficacy and safety of two doses of Norditropin(R) (somatropin) in people of short stature due to Noonan syndrome: a double randomized study of 2 years multicenter blinded trial in Japanese patients. Endoc J. 2018;65:159–74.
Academic google
Dahlgren J, Albertsson-Wikland K. GH responsiveness in children with Noonan syndrome compared with Turner syndrome. Front Endocrinol (Lausanne). 2021;12:737893.
Academic google
Chatelain P, Colle M, Nako JP, Le Luyer B, Wagner K, Berlier P, et al. Optimization of growth hormone dosing in infants born small for gestational age: an open-label, randomized study of infants during the fourth year of therapy. Horm Res Pediatrics. 2012;77:156–63.
Academic google
Deodati A, Cianfarani S. Impact of growth hormone therapy on adult height in children with idiopathic short stature: a systematic review. BMJ 2011;342:c7157.
Academic google
Collett-Solberg PF, Ambler G, Backeljauw PF, Bidlingmaier M, Biller BMK, Boguszewski MCS, et al. Diagnosis, genetics, and therapy of short stature in children: an international perspective from the growth hormone research society. Horm Res Pediatrics. 2019;92:1–14.
Academic google